Plasma-derived products and Creutzfeldt-Jakob disease: Comparison of legislation around the world

Summary Aims To analyze plasma-derived products (PD) traceability from donor selection to administration to patient. To compare PD recall legislations in France, United States (US), Canada and United Kingdom (UK) related to transmission of Creutzfeldt-Jakob disease (CJD). To develop a flowchart adapted to French context regarding information that should be given to patients. Method Literature research, consultation of national agencies and blood donation centers websites. Most recent laws and legislative texts were included. Results Twenty-five legislatives texts and 9 articles were retrieved. English donors and those who have stayed in UK more than 3 months (US) or 1 year (Europe) were excluded from plasma donations. In US and Canada, donors who lived during 5 years and more in France were also excluded. Europe and US recommended the recall of PD extracted from donors diagnosed with vCJD after donation. Recommendations concerning information to give to prescribers and patients were variable depending on the country analyzed.